November 18, 2026
Health news, explained with evidence
LIVE
CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Recall Issued for Generic Propranolol Over Potential Metal Contamination Understanding Food Science: Why Some Leftovers Freeze Better Than Others Could an mRNA Vaccine Help Treat Acne? AI-Generated Hospital Discharge Summaries Outperform Human Versions in Clinical Study FDA Leadership Uncertainty Follows Withdrawal of Commissioner Nominee

Liver-Targeted Gene Therapy Shows Promise for Rare Metabolic Disorder

🔬 Research 2 min read 👁 3

Researchers have successfully used siRNA technology in preclinical models to prevent neurological damage caused by glutaric aciduria type I. The approach targets the liver to stop the production of toxic metabolites that otherwise accumulate in the brain.

Liver-Targeted Gene Therapy Shows Promise for Rare Metabolic Disorder🔬Research

Photo: Medical Xpress

Key points

  • GA1 is a rare metabolic disorder that causes toxic buildup in the brain.
  • Researchers used siRNA to silence a liver gene, preventing the production of harmful metabolites.
  • The treatment protected mouse models from neurological damage and improved survival.

A research team led by the Duke University School of Medicine has demonstrated a potential new treatment strategy for glutaric aciduria type I (GA1), a rare inherited metabolic condition. Currently, GA1 is managed through strict, lifelong dietary restrictions, yet many patients still face severe, irreversible neurological impairment due to the buildup of toxic byproducts that damage motor function areas in the brain.

The study, published in Science Translational Medicine, utilized small interfering RNA (siRNA) to silence a specific gene in the liver responsible for the faulty breakdown of the amino acid lysine. By shifting the focus to the liver, which the researchers identified as the primary source of the toxic metabolites, the team successfully protected mouse models from neurological injury. Treated neonatal mice showed significantly improved survival rates compared to untreated groups, even when maintained on high-protein diets.

What to know: While these results in animal models are encouraging, clinical trials in humans are the necessary next step to determine safety and efficacy. Because this research is in the preclinical stage, patients should continue following their current medical care plans and consult with their physicians before considering any changes to their treatment or dietary management.

The researchers noted that this siRNA-based approach could eventually offer a more convenient alternative to restrictive diets, potentially requiring only a few injections per year. Furthermore, the study identified specific blood plasma biomarkers that may assist doctors in monitoring therapeutic progress in future human applications.

Source Medical Xpress — medicalxpress.com/news/2026-11-silencing-liver-gene-brain-rare.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.